These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38637886)

  • 1. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
    Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
    J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.
    Panowski SH; Srinivasan S; Tan N; Tacheva-Grigorova SK; Smith B; Mak YSL; Ning H; Villanueva J; Wijewarnasuriya D; Lang S; Melton Z; Ghosh A; Dusseaux M; Galetto R; Heyen JR; Sai T; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Cancer Res; 2022 Jul; 82(14):2610-2624. PubMed ID: 35294525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
    Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
    J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 5. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
    Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
    Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
    Pal SK; Tran B; Haanen JBAG; Hurwitz ME; Sacher A; Tannir NM; Budde LE; Harrison SJ; Klobuch S; Patel SS; Meza L; Dequeant ML; Ma A; He QA; Williams LM; Keegan A; Gurary EB; Dar H; Karnik S; Guo C; Heath H; Yuen RR; Morrow PK; Agarwal N; Srour SA
    Cancer Discov; 2024 Jul; 14(7):1176-1189. PubMed ID: 38583184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion.
    De Munter S; Buhl JL; De Cock L; Van Parys A; Daneels W; Pascal E; Deseins L; Ingels J; Goetgeluk G; Jansen H; Billiet L; Pille M; Van Duyse J; Bonte S; Vandamme N; Van Dorpe J; Offner F; Leclercq G; Taghon T; Depla E; Tavernier J; Kerre T; Drost J; Vandekerckhove B
    Cancer Immunol Res; 2024 Sep; 12(9):1236-1251. PubMed ID: 38874582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
    Sauer T; Parikh K; Sharma S; Omer B; Sedloev D; Chen Q; Angenendt L; Schliemann C; Schmitt M; Müller-Tidow C; Gottschalk S; Rooney CM
    Blood; 2021 Jul; 138(4):318-330. PubMed ID: 34323938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.
    Park YP; Jin L; Bennett KB; Wang D; Fredenburg KM; Tseng JE; Chang LJ; Huang J; Chan EKL
    Oral Oncol; 2018 Mar; 78():145-150. PubMed ID: 29496042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
    Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
    Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
    [No Abstract]   [Full Text] [Related]  

  • 11. CD70, a novel target of CAR T-cell therapy for gliomas.
    Jin L; Ge H; Long Y; Yang C; Chang YE; Mu L; Sayour EJ; De Leon G; Wang QJ; Yang JC; Kubilis PS; Bao H; Xia S; Lu D; Kong Y; Hu L; Shang Y; Jiang C; Nie J; Li S; Gu Y; Sun J; Mitchell DA; Lin Z; Huang J
    Neuro Oncol; 2018 Jan; 20(1):55-65. PubMed ID: 28651374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies.
    Zhang YC; Li XY; Deng Q; Ge YJ; Yi RR; Wang HJ; Wang JT; Zhou H; Kong XF; Liu RJ; Zhang YT; Li XP; He XW; Zhu HY
    Theranostics; 2024; 14(16):6249-6267. PubMed ID: 39431011
    [No Abstract]   [Full Text] [Related]  

  • 13. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia.
    Cheng J; Ge T; Zhu X; Wang J; Zeng Y; Mu W; Cai H; Dai Z; Jin J; Yang Y; Hu G; Mao X; Zhou J; Zhu L; Huang L
    Cancer Immunol Immunother; 2023 Jul; 72(7):2331-2346. PubMed ID: 36932256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
    Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma.
    Zhu G; Zhang J; Zhang Q; Jin G; Su X; Liu S; Liu F
    Cancer Immunol Immunother; 2022 Oct; 71(10):2433-2448. PubMed ID: 35249119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
    Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
    Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.
    Guo S; Lei W; Jin X; Liu H; Wang JQ; Deng W; Qian W
    Blood Adv; 2024 Jun; 8(11):2635-2645. PubMed ID: 38564778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
    Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
    J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.
    Zhang Q; Xu J; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Wang Z; Fu Q; Zheng J
    Oncol Rep; 2018 Dec; 40(6):3714-3724. PubMed ID: 30272343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.